Crown Castle Inc. (NYSE:CCI) Raymond James 44th Annual Institutional Investors Conference Transcript March 7, 2023 11:00 AM ET Executives Dan Schlanger - Chief Financial Officer Analysts Ric Prentiss - Raymond James Ric Prentiss No problem. All right. I think it’s still morning, right? It feels like a long day already. But excited. Day two, Raymond James 44th Annual Institutional Investors Conference. My 27th Raymond James Institutional Investor Conference. I’ve seen a lot of people in the room over a lot o ...

Start Time: 09:50 January 1, 0000 10:22 AM ET Bristol-Myers Squibb Company (NYSE:BMY) Cowen 43rd Annual Healthcare Conference March 07, 2023, 09:50 AM ET Company Participants Samit Hirawat - EVP, Chief Medical Officer, and Drug Development Conference Call Participants Steve Scala - Cowen and Company Mike Nedelcovych - Cowen and Company Steve Scala Welcome to the Cowen conference. Representing the company is Samit Hirawat, who is Executive Vice President and Chief Medical Officer and the Global Head of Drug ...

Atlassian Corporation (NASDAQ:TEAM) Morgan Stanley Technology, Media & Telecom Conference March 7, 2023 12:10 PM ET Company Participants Anu Bharadwaj – President and Chief Operating Officer Conference Call Participants Keith Weiss – Morgan Stanley Anu Bharadwaj How do you want to sit? Shall I do this? Keith Weiss Yes. This is my good side. Excellent. Thank you, everyone, for joining us. My name is Keith Weiss. I run the U.S. software research franchise here at Morgan Stanley. I am very pleased to have with ...

Corning Incorporated (NYSE:GLW) Morgan Stanley Technology, Media & Telecom Conference Call March 7, 2023 11:00 AM ET Company Participants Edward Schlesinger - Executive Vice President & Chief Financial Officer Conference Call Participants Meta Marshall - Morgan Stanley Meta Marshall Perfect. Welcome, everybody. Thanks so much for being here with us on the second day of the conference. I'm Meta Marshall. I cover the networking names here at Morgan Stanley. I'll start with a brief disclosure. For important di ...

Walmart Inc. (NYSE:WMT) Raymond James 44th Annual Institutional Investors Conference Call March 7, 2023 10:25 AM ET Company Participants John David - Executive Vice President and Chief Financial Officer Conference Call Participants Bobby Griffin - Raymond James Bobby Griffin Well, good morning, everybody. Thanks for joining us at our 44th Annual Institutional Investor Conference. For those that don't know me, I'm Bobby Griffin. I cover consumer Hardlines/Retail here at Raymond James. And this morning, we're ...

The Goldman Sachs Group, Inc. (NYSE:GS) RBC Capital Markets Global Financial Institutions Conference March 7, 2022 9:20 AM ET Company Participants David M. Solomon - Chairman and CEO Conference Call Participants Gerard Cassidy - RBC Capital Markets Gerard Cassidy [Abrupt Start] slides for you. They've got about a $1.4 trillion balance sheet and a market cap of $120 billion. If you add back the AOCI into book value and tangible book value, you guys traded at about 110% of book, and 120% of tangible book and ...

AbbVie Inc. (NYSE:ABBV) Conference Call Summary Company Overview - **Company**: AbbVie Inc. - **Event**: Cowen 43rd Annual Healthcare Conference Call - **Date**: March 7, 2023 Key Points Industry and Pipeline Developments - **RINVOQ**: Expected to receive approvals for new indications in rheumatology and inflammatory bowel disease (IBD) by mid-year, with potential Phase III trials for alopecia areata, hidradenitis suppurativa, and lupus starting this year [5][6] - **Oncology Pipeline**: Introduction of Teliso-V targeting non-small cell lung cancer, with a readout expected by the end of the year for potential accelerated approval [6] - **Epcoritamab**: Strong efficacy observed in DLBCL, with plans for accelerated approval and expansion into earlier treatment lines [51][52] Financial Projections and Market Dynamics - **RINVOQ and SKYRIZI**: Potential to exceed HUMIRA's peak sales, with indications expected to add a couple of billion dollars in revenue by the second half of the decade [7] - **HUMIRA Erosion**: Anticipated erosion of 35% to 55% in the U.S. market, with a current erosion rate of 37% compared to 45% in Europe [12][18] - **Biosimilars**: Seven to nine biosimilars expected to enter the market mid-year, contributing to increased volume impact in the second half of 2023 [18] Market Trends and Consumer Behavior - **Aesthetics Market**: Stability observed in the U.S. market, with economic indicators such as consumer confidence and Google searches showing positive trends, although no recovery is assumed for 2023 [26][27] - **Imbruvica**: Expected significant erosion due to competition from Brukinsa and Venclexta, with stabilization anticipated in 2024 and 2025 [29][30] Growth Drivers - **Inflammatory Bowel Disease (IBD)**: Significant growth expected for RINVOQ and SKYRIZI, with high adoption rates due to superior performance in approved indications [32][34] - **Vraylar**: Positive early results in the MDD indication, with expectations for significant market share growth [45][47] Long-term Outlook - **Pipeline Potential**: Investors may underestimate the growth potential of SKYRIZI and RINVOQ, as well as the breadth of the pipeline in oncology [59] - **Aesthetics Business**: Projected to exceed $9 billion by 2029, contrary to sell-side expectations [60] Additional Insights - **Switchback Phenomenon**: Observed in European markets where patients switch back to HUMIRA due to adverse events or loss of efficacy with biosimilars [20][24] - **Market Competition**: The migraine market is competitive, with AbbVie holding a significant share of new prescriptions, indicating strong positioning against competitors [40][41] Conclusion AbbVie is navigating a complex landscape with a robust pipeline and strategic focus on growth areas such as immunology and oncology. The company anticipates significant revenue contributions from new indications and is closely monitoring market dynamics, particularly in the face of increasing competition and the evolving biosimilar landscape.

Phillips 66. (NYSE:PSX) 51st Annual Scotia Howard Weil Energy Conference March 7, 2023 9:30 AM ET Company Participant Mark Lashier - CEO of Phillips 66 Conference Call Participant Paul Cheng - Scotiabank Paul Cheng Good morning, everyone. For our next discussion we have Mark Lashier, CEO of Phillips 66. I’m really excited to have Mark join us here today. Mark, let me cut to the chase. Since I always forget about the modern technology. Mark, let me cut with the chase. As the new CEO, you've been at the helm ...

Start Time: 13:40 January 1, 0000 2:13 PM ET Fastly, Inc. (NYSE:FSLY) Raymond James 44th Annual Institutional Investors Conference March 06, 2023, 13:40 PM ET Company Participants Ron Kisling - CFO Vernon Essi - IR Conference Call Participants Frank Louthan - Raymond James Frank Louthan All right, great. Thanks everybody for being here and joining us on the webcast. Very pleased to have Fastly here with us this year. We have CFO, Ron Kisling; and we have Vern Essi from Investor Relations here today. So let' ...

General Motors Company (NYSE:GM) Morgan Stanley Technology, Media & Telecom Conference March 6, 2023 6:20 PM ET CorporateParticipants Gil West - Chief Operating Officer, Cruise ConferenceCall Participants Brian Nowak - Morgan Stanley Brian Nowak Good afternoon, everyone. We're thrilled today to have Gil West, the COO of Cruise with us. Prior to joining Cruise, you were also the COO of Delta Airlines, and you just flew in today. Gil West Just flew in today. Brian Nowak Thanks for joining us. Gil West Great t ...